SITE011-0114

withdrawn

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE011 (ITA) · Dr. Jansen
consented 2022-07-14

AEs

Serious

Dropout signal

–

Adverse events

mild assessed

Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-08-27 (study day 35); relationship: not assessed

moderate assessed

Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-08-28 (study day 36); relationship: not assessed

mild assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-08-31 (study day 39); relationship: N

mild assessed

Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-10-26 (study day 95); relationship: N

moderate assessed

Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-01-25 (study day 186); relationship: not assessed

Data queries

No data queries.